NCT05988918 2026-03-06
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
Clinical Trials
13 trialsNCT02230176 2025-04-20
OCCLURANDOM
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT03736720 2025-01-30
Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
Roswell Park Cancer Institute
Phase 2 Terminated
NCT01525082 2024-02-06
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Stanford University
Phase 2 Completed
NCT02259725 2021-12-15
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
University of Southern California
Phase 2 Completed
NCT01869725 2021-09-22
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
University of Iowa
Phase 2 Completed
NCT02806648 2018-01-23
PALBONET
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT01056601 2017-12-28
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT02108782 2017-07-19
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
Academic and Community Cancer Research United
Phase 2 Withdrawn
NCT00869050 2016-07-25
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
Phase 2 Completed
NCT00416767 2016-05-30
Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT00027638 2013-06-18
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00466856 2012-05-18
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated